Implementation of Out-of-HOspital Administration of the Long-Acting Cabotegravir+Rilpivirine

Prior treatment

• Previous antiretroviral treatment interruption during the last 6 months or treatment interruptions for more than a month.
• Current use of any concomitant treatment as indicated in section 5.6.

Other illness

• Hepatitis B infection (section 6.2).
• History of virological failure or mutations to INSTI or NNRTI.

Other

• Contraindication for intramuscular injections
• Pregnancy or breastfeeding women, or with the desire to become pregnant in the near future.

• Patients equal or older than 18 years old
• Chronic HIV infection
• HIV patients in whom LA CAB+RPV is prescribed
• Recommended triple or dual therapy for at least 12 months, including CAB+RPV LA.
• Virologically suppression for at least 6 months: 2 consecutive determinations of undetectable viral load (plasma HIV-1 RNA levels \< 50 copies/ml ) for ≥ 6 months preceding the study randomization.
• Post-menopausal or fertile females that agree to avoid pregnancy during the study. If sexually active female; using an effective method of contraception (hormonal contraception, intra-uterine device (IUD), or anatomical sterility in self or partner) from 14 days prior to the first IMP administration until at least 13 months after the last Investigational Medicinal Product (IMP) administration;all female volunteers must be willing to undergo urine pregnancy tests at time points specified in the protocol.
• Patients which have access to an out of hospital center in which can be treated without inconvenience
• Patient who agrees to participate in the study and signs the informed consent.